

Date: 4<sup>th</sup> February, 2025

To,  
Department of Corporate Services,  
BSE Limited  
P. J. Towers,  
Dalal Street,  
Mumbai-400 001

**Scrip Code: 524604**

Dear Sir/Madam,

**Sub.: Outcome of Board of Directors Meeting of Adline Chem Lab Limited ("the Company")**

Dear Sir/ Madam,

Pursuant to Regulations 30 and 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('Listing Regulations'), we wish to inform you that the Board of Directors of the Company at its meeting held today i.e., Tuesday, 4<sup>th</sup> February, 2025 at Registered Office of the Company has inter alia discussed following Agendas:

- (1) Considered and approved the Unaudited Financial Results along with Limited Review Report of the Company for the Quarter and Nine months ended December 31<sup>st</sup>, 2024 (**Enclosed herewith**);

The meeting of Board of Directors of the Company commenced at 12:00 P.M. and concluded at 05:45 P.M.

You are requested to kindly take the same on record and acknowledge.

**Yours faithfully,**

Thanking You,

**For, Adline Chem Lab Limited**

---

**Ritu Singh**  
**Company Secretary & Compliance Officer**  
**Membership No.: A24934**

**Encl: as above**


CIN : L24231GJ1988PLC010956

**ADLINE CHEM LAB LIMITED** (Formerly Kamron Laboratories Limited)

**Registered Office :** 403, Sarthik II, Opp. Rajpath Club, S. G. Highway, Bodakdev, Ahmedabad - 380 054, Gujarat, INDIA.  
**Phone:** 079 2687 0954 | **E-mail :** secretarial.adlinechemlab@gmail.com | **Website:** www.kamronlabs.com


**The Board of Directors****ADLINE CHEMLAB LIMITED****Independent Limited Review Report on the quarterly unaudited Standalone Financial Results of the Company pursuant to the regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended**

1. We have reviewed the accompanying statement of unaudited financial results of Adline Chem Lab Ltd. (the "Company") for the quarter ended December 31, 2024 which include financial results ended on that date together with the relevant notes thereon (the "Statement"). The Statement has been prepared by the Company pursuant to Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (The "Listing Regulations, 2015"). The Statement is the responsibility of the Company's management and has been approved by the Board of Directors. Our responsibility is to issue a report on the Statement based on our review.
2. This Statement, which is the responsibility of the Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" (Ind AS 34), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India (ICAI). A review of interim financial information consists of making inquiries, primarily of company's personnel responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under Section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion. We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33 (8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.



4. Based on our review conducted as above, nothing except for the point no. 5 stated below has come to our attention that causes us to believe that the Statement has not been prepared in all material respects in accordance with applicable Indian Accounting Standard ('Ind AS') and other recognised accounting practices and policies, and has not disclosed the information required to be disclosed in terms of Listing Regulations including the manner in which it is to be disclosed, or that it contains any material misstatement.
5. We draw attention to the related party transaction entered into by the Company with Vivanza Lifescience Private Limited, an unlisted entity within the group. The transaction was conducted in the ordinary course of business for which the entities have entered into an agreement and complies with the provisions of Section 188 of the Companies Act, 2013. The Company has not obtained prior shareholders' approval for this transaction as set forth in Regulation 23(4) of the Listing Regulation Act, 2015. Our opinion is not modified in respect of this matter.

**For Jain Kedia & Sharma**  
**Chartered Accountants**  
**FRN: 103920W**



*Tarak Shah*

**Tarak Shah**  
**Partner**

**Place: Ahmedabad**

**Date: February 04, 2025**

**Membership No. 182100**

**UDIN:25182100BMOCZQ7152**

**ADLINE CHEMLAB LIMITED**  
 Regd. Office: 403, Sarthik 2, Opp. Rajpath Club, S. G. Highway, Ahmedabad 380054  
 CIN : L24231GJ1988PLC010956  
 Phone: 079-2687052/53 email: secretarialadlinechemlab@gmail.com website:www.adlinechem.com  
**STANDALONE UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTH ENDED 31st December, 2024**

Particulars	Quarter Ended			Nine Month Ended		Year Ended
	31st Dec 2024	30th Sep 2024	31st Dec 2023	31st Dec 2024	31st Dec 2023	31st Mar 2024
	Unaudited	Unaudited	Restated	Unaudited	Restated	Restated
Revenue from operations	-	-	-	-	-	-
Other income	-	-	-	-	-	-
<b>Total income</b>	-	-	-	-	0.01	0.01
					0.01	0.01
<b>Expenses</b>						
Cost of materials consumed	-	-	-	-	-	-
Purchase of Stock in Trade	-	-	-	-	-	-
Changes in inventories of finished goods, Stock-in-Trade and work-in-progress	-	-	-	-	-	-
Employee benefits expense	4.72	4.71	0.50	13.04	3.09	4.36
Finance costs	3.48	3.39	3.15	10.18	9.22	12.44
Depreciation and amortization expense	-	-	-	-	-	-
Other expenses	4.95	2.02	-0.43	13.52	8.37	13.49
<b>Total expenses</b>	13.14	10.13	3.22	36.74	20.67	30.29
<b>Profit/(loss) before exceptional items and tax</b>	(13.14)	(10.13)	(3.22)	(36.74)	(20.66)	(30.28)
Exceptional Items	-	-	-	-	-	-
<b>Profit/(loss) before tax</b>	(13.14)	(10.13)	(3.22)	(36.74)	(20.66)	(30.28)
<b>Tax expense:</b>	0.88	(0.86)	(0.72)	(2.58)	(2.25)	(3.10)
Current tax	-	-	-	-	(2.32)	-
Deferred tax	0.88	(0.86)	(0.79)	(2.58)	0.07	(3.16)
Prior period tax	-	-	0.07	-	-	0.07
<b>Profit (Loss) for the period from continuing operations</b>	(12.26)	(9.27)	(2.49)	(34.16)	(18.41)	(27.18)
Profit/(loss) from discontinued operations	-	-	-	-	-	-
Tax expense of discontinued operations	-	-	-	-	-	-
Profit/(loss) from Discontinued operations (after tax)	-	-	-	-	-	-
<b>Profit/(loss) for the period</b>	(12.26)	(9.27)	(2.49)	(34.16)	(18.41)	(27.18)
<b>Other Comprehensive Income</b>	0.46	0.46	-	1.37	-	0.05
Items that will not be reclassified to profit or loss (Net off tax)	0.46	0.46	-	1.37	-	0.05
Benefit due to actuarial valuation of gratuity	0.61	0.61	-	1.84	-	0.06
Deferred tax	(0.15)	(0.15)	-	(0.46)	-	(0.02)
Items that will be reclassified to profit or loss (Net of tax)	-	-	-	-	-	-
<b>Total Comprehensive Income for the period</b>	(11.81)	(8.81)	(2.49)	(32.79)	(18.41)	(27.13)
Paid-up equity share capital (Face Value of the Share Rs. 10/- each)	585.00	585.00	585.00	585.00	585.00	585.00
<b>Earnings per equity share [Not Annualised]:</b>						
Basic	(0.02)	(0.02)	(0.00)	(0.06)	(0.03)	(0.05)
Diluted	(0.02)	(0.02)	(0.00)	(0.06)	(0.03)	(0.05)

**Notes:**

- This statement has been prepared in accordance with the Indian Accounting Standards (Ind AS) as prescribed under Section 133 of the Companies Act, 2013 Accounting Standards Rules, 2015 (as amended). The statutory auditors of the company have carried out limited review of the financial results for the quarter ended December 31, 2024.
- These results have been reviewed and recommended for adoption by the Audit Committee in its meeting held on February 04, 2025, and approved by the Board of Directors at its meeting held on February 04, 2025. The Statutory Auditors Report does not have any qualification | modification.

For, ADLINE CHEMLAB LIMITED

SARANG BHARATBHAI PATHAK  
 MANAGING DIRECTOR  
 DIN:02663344

Place: Ahmedabad  
 Date: February 04, 2025

